Kintor Pharmaceutical Limited (HKEX: 9939), a China-based clinical-stage biotechnology company, announced on Wednesday that it has dosed the first batch of subjects in its phase one clinical trial of GT20029 in China.

The phase I trial, a randomised, double-blind, placebo-controlled study, is intended to assess the safety, tolerability, and pharmacokinetics of the product (gel/tincture) subsequent to the topical single and multiple ascending dose administration in healthy patients.

According to Kintor Pharmaceutical, the product is the first topical Proteolysis Targeting Chimera compound globally to enter the clinical stage. It received approval from The China Center for Drug Evaluation (CDE) and the US Food and Drug Administration (FDA) for phase one clinical trial for treating androgenetic alopecia and acne in April 2021 and July 2021 separately.